Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
Sterile Urea is an injectable small-molecule osmotic agent approved in 1976 by Pfizer. It is used to reduce intracranial pressure and intraocular pressure in acute settings, primarily in neurology and ophthalmology. The drug works by creating an osmotic gradient that draws fluid from tissues into the intravascular space.
Product is in advanced age with no active commercial growth signals; small team supporting legacy indication base.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke
Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas as Well as Subnuclei of the Spinal Trigeminal Nucleus
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Worked on STERILE UREA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sterile Urea offers minimal career advancement opportunity as a legacy injectable with no linked job openings and approaching end-of-lifecycle status. Roles available are primarily in maintenance, regulatory compliance, and niche clinical support rather than commercial growth or innovation.